Filter posts

AP: Groups Claim Insurance Discrimination

In this August 18 article, Ricardo Alonso-Zaldivar highlights assertions by patient groups that new insurance …

Docs to FDA: Biosimilars should have different names than branded drugs

Yesterday, Fierce Biotech highlighted a letter written by more than 10 medical associations and 20 individual specialists …

New study shows hepatitis C burden may ease in future

Anew study published in the Annals of Internal Medicine projects that the prevalence of hepatitis …

NYT Columnist: Insurance Industry “Looking at the Costs of Sovaldi in the Wrong Way”

Margot Sanger-Katz’s article on a new drug that treats hepatitis C notes that despite the …

Treating Hepatitis C: Too Costly Not to Act

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

AIR 340B New Report: Contract Pharmacy Growth in 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …

Scientific American WorldView Super Session: The Future of Global Innovation

The sixth annual Scientific American WorldView super session packed the room late in the day …

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading …

Gates Foundation Issues Biotech Call to Action

Today, Trevor Mundel from the Bill & Melinda Gates Foundation discussed the untapped potential of …